Tilray Brands (NASDAQ:TLRY) Rating Lowered to “Sell” at Wall Street Zen

Tilray Brands (NASDAQ:TLRY) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

TLRY has been the topic of several other reports. ATB Cormark Capital Markets upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 10th. Canaccord Genuity Group began coverage on shares of Tilray Brands in a research report on Tuesday, January 27th. They set a “hold” rating on the stock. Roth Mkm reduced their price objective on shares of Tilray Brands from $20.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday, January 20th. Zacks Research upgraded Tilray Brands from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tilray Brands in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $13.33.

Tilray Brands Trading Up 2.1%

NASDAQ:TLRY opened at $7.21 on Friday. The company has a market cap of $840.04 million, a P/E ratio of -0.33 and a beta of 1.95. Tilray Brands has a twelve month low of $3.51 and a twelve month high of $23.20. The business has a 50 day moving average price of $8.29 and a two-hundred day moving average price of $10.95. The company has a quick ratio of 1.72, a current ratio of 2.81 and a debt-to-equity ratio of 0.19.

Tilray Brands (NASDAQ:TLRY) last posted its quarterly earnings data on Thursday, January 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.12. Tilray Brands had a negative net margin of 251.69% and a negative return on equity of 6.35%. The company had revenue of $217.51 million for the quarter, compared to the consensus estimate of $211.15 million. During the same period last year, the company earned ($0.03) earnings per share. As a group, analysts expect that Tilray Brands will post -0.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Tilray Brands

Institutional investors have recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC acquired a new stake in Tilray Brands in the fourth quarter valued at $38,000. Schonfeld Strategic Advisors LLC increased its stake in shares of Tilray Brands by 4.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 144,358 shares of the company’s stock worth $1,304,000 after purchasing an additional 6,182 shares during the last quarter. IFP Advisors Inc raised its holdings in shares of Tilray Brands by 14.3% in the 4th quarter. IFP Advisors Inc now owns 60,318 shares of the company’s stock valued at $545,000 after purchasing an additional 7,541 shares during the period. Integrated Wealth Concepts LLC lifted its stake in Tilray Brands by 33.8% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 36,977 shares of the company’s stock valued at $64,000 after purchasing an additional 9,341 shares during the last quarter. Finally, CreativeOne Wealth LLC grew its holdings in Tilray Brands by 12.2% during the third quarter. CreativeOne Wealth LLC now owns 87,134 shares of the company’s stock worth $151,000 after purchasing an additional 9,452 shares during the period. 9.35% of the stock is currently owned by institutional investors and hedge funds.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.